Drug Giant Bristol Partners with Illumina on Diagnostic Test to Use with Updivo
Bristol-Myers Squibb is partnering with Illumina to develop diagnostic tests that will pair with Bristol’s oncology immunotherapies.
The companies plan to develop a diagnostic version of the Illumina TruSight Oncology 500 assay to measure potentially predictive biomarkers, including Tumour Mutation Burden (TMB).
The partnership expands Illumina’s oncology offerings for NextSeq 550Dx.
Bristol-Myers Squibb’s clinical development program includes 24 clinical-stage molecules designed to target different immune system pathways across more than 50 types of cancers, and through its translational capabilities, has identified a number of potentially predictive biomarkers, including PD-L1, TMB, MSI-H/dMMR and LAG-3.
“Through our deep understanding of cancer biology and emerging research, we recognize the importance for physicians to know each patient’s biomarker status to help fight their cancer in a more personalized way,” said Saurabh Saha, a Bristol Senior Vice President, in the press release.
Garret Hampton, Illumina’s EVP of clinical genomics added: “With BMS’ leading position in immunotherapy development, we see tremendous promise in this partnership to co-develop next-generation sequencing-based diagnostics that can identify effective therapeutic combinations and provide global access to these targeted drugs.”